AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes

The spotlight at the American Heart Association (AHA) 2025 Annual Scientific Sessions turned toward an unexpected debate over sotagliflozin, a dual SGLT1/2 inhibitor developed by Lexicon Pharmaceuticals (NASDAQ: LXRX). While the company’s presentation highlighted new analyses suggesting improved outcomes in patients with heart failure with preserved ejection fraction (HFpEF), the absence of diabetes in this subgroup drew mixed reactions across the cardiology community. The discussion underscored the drug’s evolving clinical positioning beyond glucose control and into broader cardiovascular applications that could reshape its commercial relevance.

Lexicon’s stock saw brief volatility following the session, as investors interpreted the presentation both as a scientific milestone and a commercial risk. While no new regulatory filings were announced, traders viewed the emerging HFpEF data as a potential pivot point that could expand the sotagliflozin franchise beyond its existing approval base.

How the AHA 2025 data on sotagliflozin challenged existing boundaries between diabetic and non-diabetic heart failure

The AHA 2025 discussion revisited a familiar yet contentious frontier in cardiometabolic therapy: whether SGLT-class inhibitors provide consistent benefits in heart failure patients who do not have diabetes. For sotagliflozin, the answer remains nuanced. Earlier Phase 3 studies such as SCORED and SOLOIST-WHF primarily involved diabetic patients, where the drug demonstrated significant reductions in cardiovascular deaths and hospitalizations. However, the new AHA abstract—though limited in sample size—hinted at comparable trends in non-diabetic HFpEF populations, prompting fresh curiosity about its dual mechanism.

Cardiologists attending the session indicated that the SGLT1 component, which influences intestinal glucose absorption and myocardial energetics, could theoretically enhance cardiac efficiency in HFpEF independent of glycemic status. While such hypotheses align with observed class effects from dapagliflozin and empagliflozin, experts emphasized that sotagliflozin remains an outlier given its hybrid pharmacology. The broader implication, they said, is that cardiovascular benefit in HFpEF may not require diabetic comorbidity—a concept now gaining traction in guidelines and investor forecasts alike.

Clinical scientists familiar with the presentation described the data as “signal-generating” rather than confirmatory. The presentation did not reveal a new randomized trial but rather a post-hoc pooled analysis suggesting a reduction in heart-failure-related hospitalization risk and improved Kansas City Cardiomyopathy Questionnaire (KCCQ) scores among patients with preserved ejection fraction regardless of diabetes status. Yet without an official publication or peer-reviewed dataset, the interpretation remains cautious.

Why investors are watching Lexicon Pharmaceuticals’ sotagliflozin trajectory amid mixed clinical clarity

For Lexicon Pharmaceuticals, the conversation around sotagliflozin at AHA 2025 arrives at a critical inflection point. The company has faced persistent scrutiny regarding commercialization strategy and financial sustainability since the drug’s U.S. Food and Drug Administration (FDA) approval in 2023 for heart failure with or without type 2 diabetes. Although that approval broadened its market eligibility, uptake has lagged behind rival SGLT2 inhibitors marketed by AstraZeneca and Boehringer Ingelheim, leaving analysts to question whether a niche HFpEF indication could reinvigorate sales momentum.

Lexicon’s share price has traded in a narrow band for much of 2025, reflecting investor fatigue after years of delayed milestones and capital raises. Following the AHA 2025 session, LXRX briefly spiked intraday before settling back, as fund managers balanced enthusiasm over the possible HFpEF expansion against uncertainty about payer coverage and trial timelines. Institutional sentiment has been cautiously neutral, with short interest remaining moderate and no major rating changes from brokerage analysts.

Financial observers suggested that confirmation of sotagliflozin’s benefit in non-diabetic HFpEF could justify renewed valuation models projecting annual revenue potential approaching $1 billion by 2030. Yet absent new trial announcements, that optimism remains speculative.

Market strategists noted that Lexicon may now face a strategic choice: either initiate a dedicated Phase 3 HFpEF-without-diabetes study or seek label expansion based on class precedent if regulatory pathways permit. The latter could shorten timelines but might invite comparative scrutiny from established players like AstraZeneca’s Farxiga and Eli Lilly’s Jardiance.

What clinical experts are debating about the mechanism of sotagliflozin in HFpEF without diabetes

The mechanistic question driving post-AHA 2025 debate is whether sotagliflozin’s dual inhibition of SGLT1 and SGLT2 yields incremental cardiovascular benefits beyond what traditional SGLT2 inhibitors achieve. Specialists at the session described sotagliflozin as having a unique metabolic footprint. By targeting intestinal SGLT1, it modulates glucose absorption, enhances ketone utilization, and may improve myocardial energy efficiency—a particularly attractive feature in HFpEF, where diastolic dysfunction often stems from metabolic stiffness rather than ischemic injury.

Nevertheless, skeptics emphasized the risk of over-interpreting early trends. Without randomized evidence in non-diabetic HFpEF populations, it remains unclear whether the observed improvements reflect true drug efficacy or confounding from patient selection. Several panelists noted that sotagliflozin’s absorption-related adverse-event profile could differ in non-diabetic patients, making broad generalization premature.

Still, mechanistic curiosity is running high. Academic cardiologists underscored that the field has shifted rapidly toward viewing heart failure as a systemic metabolic disorder, and SGLT-targeting drugs—regardless of diabetes—fit neatly into that paradigm. Sotagliflozin’s inclusion of an SGLT1 blockade may thus represent the next frontier, particularly if it can modulate myocardial substrate utilization more efficiently than single-target inhibitors.

If Lexicon elects to pursue a non-diabetic HFpEF indication, observers expect it will design a mid-sized proof-of-concept trial evaluating exercise tolerance, left-atrial strain, and KCCQ improvements rather than relying solely on hospitalization endpoints. Such endpoints would mirror the evolving direction of HFpEF research seen with EMPEROR-Preserved and DELIVER trials, thereby inviting potential regulatory comparability.

How sotagliflozin’s evolving profile could shift competitive dynamics in the SGLT inhibitor market

The SGLT inhibitor market is entering a second competitive phase, with differentiation increasingly hinging on cardiorenal indications rather than glycemic control. Within that context, sotagliflozin’s potential to demonstrate benefit in HFpEF without diabetes could redefine its positioning. While AstraZeneca’s dapagliflozin and Eli Lilly’s empagliflozin dominate sales, both target the SGLT2 pathway exclusively. A dual SGLT1/2 inhibitor showing benefit across the ejection-fraction spectrum could disrupt the existing equilibrium by appealing to cardiologists seeking broader mechanistic coverage.

Industry analysts described this scenario as a “long-tail opportunity” for Lexicon Pharmaceuticals. Even a modest market share in HFpEF could meaningfully lift revenues, given that the global prevalence of preserved-ejection-fraction heart failure exceeds 60 million cases worldwide. The key, they stressed, is demonstrating clinical durability without triggering new safety concerns.

From a policy standpoint, the potential expansion of SGLT inhibitors into non-diabetic HFpEF could further blur the lines between metabolic and cardiovascular therapeutics. Payers may face pressure to align formulary coverage across class effects, especially if guideline committees continue endorsing SGLT therapy for all heart-failure phenotypes. For Lexicon, that convergence could translate into easier market access—provided new evidence supports it.

What this discussion signals for cardiology research and investor sentiment going into 2026

The debate over sotagliflozin at AHA 2025 offers a preview of where cardiometabolic research is headed. As boundaries between endocrine and cardiac medicine erode, therapies once confined to diabetes care are emerging as mainstream tools for heart-failure management. The absence of definitive sotagliflozin data in non-diabetic HFpEF does not diminish the significance of the question—it amplifies it.

Analysts covering Lexicon expect that 2026 will determine whether the company pivots toward new trials or deepens existing indications through real-world evidence. Either path could reshape the firm’s trajectory as investors increasingly favor biotech firms with multi-organ pipeline strategies.

For now, Lexicon finds itself in a rare position where science and sentiment intersect. Sotagliflozin’s presence at AHA 2025—though inconclusive—secured the company renewed visibility among cardiologists and fund managers alike. Whether that translates into durable market traction will depend less on the data already shown and more on how decisively the next phase of research is executed.

As the AHA 2025 dust settles, the key narrative remains: sotagliflozin is at the frontier of redefining heart-failure therapy beyond diabetes. The cardiology community awaits proof; investors await momentum. In that intersection lies Lexicon’s next chapter.